Navigation Links
Study Finds Pre-Hospital Administration Of Bivalirudin Substantially Improves Outcomes Compared To Heparin In Heart Attack Patients
Date:10/30/2013

SAN FRANCISCO, Oct. 30, 2013 /PRNewswire-USNewswire/ -- According to a new study, administering the blood thinner bivalirudin to patients experiencing an ST-elevation myocardial infarction (STEMI, the most serious form of a heart attack) in a pre-hospital setting can reduce the risk of death and major bleeding complications compared to heparin with optional use of glycoprotein IIb/IIIa inhibitors.

Findings from the EUROMAX trial were reported today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. Results of the trial were simultaneously published today in the New England Journal of Medicine.

The EUROMAX trial evaluated the administration of anticoagulant therapy prior to hospital admission by an emergency medical team. The trial compared a heparin-based strategy (with or without glycoprotein IIb/IIIa receptor inhibitors (GPIs) to a bivalirudin-based strategy. The primary endpoint was a composite incidence of death or non-coronary-artery-bypass-graft related protocol major bleeding at 30 days, assessed by intention to treat.

While bivalirudin has been compared to other blood thinners in hospital settings, the EUROMAX study is the first to evaluate these anticoagulant therapy options prior to hospital admission and in conjunction with newer P2Y12 inhibitors such as prasugrel and ticagrelor. The randomized, international, prospective, open-label ambulance trial enrolled 2,198 patients with STEMI and intended for primary PCI, presenting either via ambulance or to centers where PCI is not performed.

Patients either received bivalirudin (n=1,089) or heparin (n=1,109) at guideline-recommended doses (with or without routine or bailout GPI).

After 30 days, patients that received bivaliru
'/>"/>

SOURCE Cardiovascular Research Foundation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds
2. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
3. Acacia Pharma Initiates Phase II Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)
4. Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors
5. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
6. Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis
7. New Study Shows Promise For First Effective Medicine To Treat Cocaine Dependence
8. Philips and RealView Imaging conclude worlds first study to evaluate live 3D holographic imaging in interventional cardiology
9. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
10. Kinex Announces First Patient Dosed in Phase Ib Study of Oraxol, an Orally Dosed Paclitaxel
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
(Date:10/22/2014)... and SHANGHAI , Oct. 22, 2014 ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... offer Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies ... Under the terms of the collaboration, ... the laboratory component of Foundation Medicine,s FoundationOne® assay at ...
(Date:10/20/2014)... , Oct. 20, 2014  Luoxis Diagnostics, Inc., ... AMPE), today announced that its academic collaborators will ... research potential for its novel RedoxSYS Diagnostic System, ... in the body in response to injury or ... ORP as a clinical marker will be presented ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... June 20 Advocate Christ,Medical Center in Oak Lawn, ... the Chicago area, the only one in the Advocate ... are using a glue-like liquid for,the successful treatment of ... procedure, Thomas J. Grobelny MD, of,the medical center,s Neurosciences ...
... SYDNEY, Australia, June 19 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... the U.S. Food,and Drug Administration (FDA) have reached ... for bronchiectasis via the Special,Protocol Assessment process., ... a clinical trial protocol,intended to form the primary ...
Cached Medicine Technology:Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 3
(Date:10/22/2014)... OR (PRWEB) October 22, 2014 During ... California’s fresh water supply runs dangerously low, Southern Oregon’s ... Southern Oregon’s rivers, despite the lowest mountain snow pack ... in late summer and early autumn.* That was the ... of the new book “Hiking Southern Oregon,” during an ...
(Date:10/22/2014)... 2014 Healthcare professionals who are ... education at home or on-the-go via laptops, tablets ... brand new, premium Seminar-on-Demand CE courses. The new ... 2,000 hours of CE course offerings, ... experience. With such a diverse library, there’s something ...
(Date:10/22/2014)... are only 24 hours in a day, that doesn’t seem to ... within their busy schedules for exercise and fitness. Fortunately, one does ... in shape. Here are five ways you can reach your fitness ... Your Commute , Consider riding a bike or taking the bus ... routine. If you must use your car to get to work, ...
(Date:10/22/2014)... PA (PRWEB) October 22, 2014 Richard ... as an industry leader with over 25 years experience. ... team leader in the areas related to EDI, B2B ... Carlson is an Editorial Advisory Board member for Pharmaceutical ... Educator. Blue Fin Group is a management and ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... and length may be showing a genetic propensity for obesity ... genes have been linked to increased body fat, but the ... lean muscle, the researchers said. At 1 year, kids ... 2 and 3, however, these genes were linked to excessive ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... , , OAKLAND, Calif., Dec. 7 ... Kaiser Permanente, has been named a 2010 Premier 100 IT ... from a broad range of companies recognized ... effectively managed IT strategies. , "Phil,s contributions have helped Kaiser ...
... , Amendment precludes use of federal dollars ... in Senate bill , Oppose making people pay for other people,s ... support for the Nelson-Hatch-Casey Amendment to the Senate health reform bill ... the position in a Dec. 7 letter to all U.S. senators, ...
... demonstrate a clear positive association between adolescent fitness and ... Southern California and colleagues in Sweden find that better ... on a range of intelligence tests and more ... adolescence and adulthood, the central nervous system displays considerable ...
... with the disease should be vaccinated along with other ... News) -- Swine flu is more likely than seasonal ... cell disease, a new study has found. , Johns ... 118 children with sickle cell disease treated for any ...
... , PLYMOUTH, Mich., Dec. 7 The Board of ... Mohsen Sohi will join the Management Board of Freudenberg & Co. ... Sost, who will be retiring. In his new role, Dr. Sohi ... , To assume this role, Dr. Sohi will leave his current ...
... , Group Offers ... WASHINGTON, Dec. 7 Opponents of health reform are fear-mongering ... the lobbying messages of the insurance industry. While the public ... delay a vote, the messages being delivered during that debate ...
Cached Medicine News:Health News:Kaiser Permanente CIO Philip Fasano Named One of Computerworld's Top 100 IT Leaders for 2010 2Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 2Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 3Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 4Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 5Health News:Fit teenage boys are smarter 2Health News:Swine Flu Can Batter Kids With Sickle Cell 2Health News:Freudenberg-NOK CEO Accepts New Position 2Health News:Senate Opponents Delivering 'Chicken Little' Mistruths Crafted to Sow Fear on Health Reform, says Consumer Watchdog 2Health News:Senate Opponents Delivering 'Chicken Little' Mistruths Crafted to Sow Fear on Health Reform, says Consumer Watchdog 3Health News:Senate Opponents Delivering 'Chicken Little' Mistruths Crafted to Sow Fear on Health Reform, says Consumer Watchdog 4Health News:Senate Opponents Delivering 'Chicken Little' Mistruths Crafted to Sow Fear on Health Reform, says Consumer Watchdog 5
Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
Features a built-in throat illuminator, providing 30% more magnification and twice the field of view. Adjustable focus....
... Novus Spectra photocoagulator delivers power and ... solid-state (DPSS) technology. Diode side-pumping technology ... the compact Novus Spectra system, and ... beam output and system reliability from ...
A standard, durable and reliable indirect....
Medicine Products: